Education
About Us
Working with TipRanks
Follow Us
Bioventus, Inc. (BVS)
:BVS
BVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.02 - $14.38
Previous CloseN/A
Volume116.12K
Average Volume (3M)457.19K
Market Cap
$507.65M
Enterprise Value$966.47M
Total Cash (Recent Filing)$22.80M
Total Debt (Recent Filing)$345.93M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Aug 06, 2025EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding66,357,610
10 Day Avg. Volume446,107
30 Day Avg. Volume457,191
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.90
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit2.54
Enterprise Value/Ebitda25.35
Forecast
1Y Price Target
$11.33Price Target Upside79.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Business ExecutionThe company is shifting from a recovery story to an execution story, succeeding in improving commercial execution across major business units.
Cash FlowBioventus is expected to deliver significant cash flow acceleration by lowering inventory, interest expense, and one-time cash costs.
Bears Say
Earnings PressureAdjusted EBITDA should be weaker due to revenue headwinds and more normalized expense levels expected compared to reduced spending previously.
Revenue ChallengesQ1/H1 organic revenues should be more challenged given two fewer selling days, a pull-forward of HA orders, and continued BGS distributor choppiness.
Bioventus News
BVS FAQ
What was Bioventus, Inc.’s price range in the past 12 months?
Bioventus, Inc. lowest stock price was $6.02 and its highest was $14.38 in the past 12 months.
What is Bioventus, Inc.’s market cap?
Bioventus, Inc.’s market cap is $507.65M.
When is Bioventus, Inc.’s upcoming earnings report date?
Bioventus, Inc.’s upcoming earnings report date is Aug 06, 2025 which is tomorrow.
How were Bioventus, Inc.’s earnings last quarter?
Bioventus, Inc. released its earnings results on May 06, 2025. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.025 by $0.055.
Is Bioventus, Inc. overvalued?
According to Wall Street analysts Bioventus, Inc.’s price is currently Undervalued.
Does Bioventus, Inc. pay dividends?
Bioventus, Inc. does not currently pay dividends.
What is Bioventus, Inc.’s EPS estimate?
Bioventus, Inc.’s EPS estimate is 0.16.
How many shares outstanding does Bioventus, Inc. have?
Bioventus, Inc. has 66,357,610 shares outstanding.
What happened to Bioventus, Inc.’s price movement after its last earnings report?
Bioventus, Inc. reported an EPS of $0.08 in its last earnings report, beating expectations of $0.025. Following the earnings report the stock price went down -11.807%.
Which hedge fund is a major shareholder of Bioventus, Inc.?
Currently, no hedge funds are holding shares in BVS
Bioventus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (79.27% Upside)
$11.33 (79.27% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 488.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 10.6%
Last 30 Days ▼ 10.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.96%
12-Months-Change
Fundamentals
Return on Equity
-19.79%
Trailing 12-Months
Asset Growth
-12.95%
Trailing 12-Months
Company Description
Bioventus, Inc.
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
BVS Company Deck
BVS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted solid growth in certain segments such as Surgical Solutions and the expansion into the PRP market, along with increased EPS and reaffirmation of financial guidance. However, these positives were tempered by a decline in overall revenue, foreign currency losses, and challenges in the international segment.Read More>BVS Stock 12 Month Forecast
Average Price Target
$11.33
▲(79.27%Upside)
Technical Analysis
Ownership Overview
32.15% Insiders
8.13% Mutual Funds
0.20% Other Institutional Investors
50.54% Public Companies and
Individual Investors